Nichol McBee

Medicine & Life Sciences

1. Cerebral Hemorrhage 100%
2. Hemorrhage 80%
3. Tissue Plasminogen Activator 61%
4. Minimally Invasive Surgical Procedures 49%
5. Hematoma 25%
6. Cavernous Hemangioma 22%
7. Phase III Clinical Trials 21%
8. Odds Ratio 19%
9. Stroke 18%
10. Intracranial Aneurysm 18%
11. Safety 18%
12. Clinical Trials 17%
13. Placebos 16%
14. Mortality 16%
15. Drainage 14%
16. Randomized Controlled Trials 14%
17. Intracranial Hemorrhages 14%
18. Aneurysm 14%
19. Hypothermia 13%
20. Outpatients 13%
21. Data Analysis 12%
22. Therapeutics 12%
23. Central Nervous System Cavernous Hemangioma 12%
24. Coronavirus 12%
25. Biomarkers 11%
26. Catheters 10%
27. Hypertensive Intracranial Hemorrhage 10%
28. Tomography 9%
29. Nervous System 9%
30. Subarachnoid Hemorrhage 9%
31. Root Cause Analysis 8%
32. Meta-Analysis 8%
33. Intracranial Pressure 8%
34. Post-Exposure Prophylaxis 8%
35. Logistic Models 8%
36. Survivors 8%
37. Severe Acute Respiratory Syndrome 8%
38. Infections 7%
39. Intracranial Hypertension 7%
40. Doppler Transcranial Ultrasonography 7%
41. Nicardipine 7%
42. Hydroxychloroquine 7%
43. Blood Pressure 7%
44. Transfusion Reaction 7%
45. Confidence Intervals 7%
46. Protective Agents 7%
47. Internal Capsule 7%
48. Cardiac Rehabilitation 7%
49. Atorvastatin 6%